Author

R. Fulton

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Approach:statistical model· 2 Research Focus:variant calling· 2 Assay:whole-exome sequencing· 2 Assay:whole-genome sequencing· 2 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

C. A. Miller· 2 shared E. R. Mardis· 2 shared A. Al-Shamkhani· 1 shared A. F. Vallejo· 1 shared A. Raue· 1 shared A. W. E. Purcell· 1 shared B. Mbiribindi· 1 shared C. Retiere· 1 shared

Activity by Year

2017-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. A. Miller

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Genomic and transcriptomic somatic alterations of hepatocellular carcinoma in non-cirrhotic livers

Z. L. Skidmore, J. Kunisaki, Y. Lin, K. C. Cotto, E. K. Barnell, J. Hundal, K. Krysiak, V. Magrini, L. Trani, J. R. Walker, R. Fulton, E. Brunt, C. A. Miller, R. K. Wilson, E. R. Mardis, , O. L. Griffith

This study identifies genomic and transcriptomic alterations in non-cirrhotic hepatocellular carcinoma, revealing recurrent mutations and structural variants that may contribute to tumorigenesis.

bioRxiv · Dec 14, 2021Cancer Biology

Single-cell immune profiling with TCR clonotype barcoding identifies biomarker signatures that predict response to immune checkpoint blockade

D. Lee, R. Fulton, M. Manne, L. Schweizer, A. Raue

The paper identifies a gene expression signature predicting response to immune checkpoint blockade using TCR clonotype barcoding in single-cell data from a small cohort, validated in larger studies.

bioRxiv · Apr 13, 2021 · PreprintImmunology

Peptide:MHC dependent activation of natural killer cells through KIR2DS2 generates anti-tumor responses

P. Rettman, M. D. Blunt, B. Mbiribindi, R. Fulton, R. Schittenhelm, A. F. Vallejo, L. Bastidas-Legarda, M. E. Polak, R. Ayala, A. W. E. Purcell, A. Al-Shamkhani, C. Retiere, S. I. Khakoo

This study shows that activating NK cells via KIR2DS2 with a peptide:MHC vaccine generates anti-tumor responses and identifies XPO1 as a cancer-associated ligand for KIR2DS2.

bioRxiv · Apr 15, 2020 · PreprintImmunology

Temporal and Clonal Progression in a Pediatric Ependymoma Patient Through Multiple Treatments

C. A. Miller, S. Dahiya, T. Li, R. Fulton, M. D. Smyth, G. P. Dunn, J. B. Rubin, E. R. Mardis

This study tracks the molecular evolution of a pediatric ependymoma through multiple treatments, revealing how therapy shapes tumor subclonal diversity and neo-antigen landscapes.

bioRxiv · Mar 11, 2017Cancer Biology